Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 311 to 320 of 321 total matches.

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
. FIBRIC ACID DERIVATIVES — Fibrates are primarily used to lower triglycerides. They activate the nuclear ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Treatment of Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021  (Issue 1635)
of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human ...
Onychomycosis is caused most commonly by Trichophyton rubrum or T. mentagrophytes. About 10% of all persons worldwide and 40% of those ≥60 years old are believed to have the disease. Risk factors include older age, diabetes, poor peripheral circulation, smoking, HIV infection, psoriasis, and immunosuppression. Left untreated, onychomycosis can cause nail plate destruction, ingrown nails, and (particularly in patients with diabetes) secondary infections. Guidelines on treatment of onychomycosis have been published.
Med Lett Drugs Ther. 2021 Oct 18;63(1635):164-8 |  Show IntroductionHide Introduction

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
is a peptide hormone with activity at both glucosedependent insulinotropic polypeptide (GIP) and glucagon ...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-84 |  Show IntroductionHide Introduction

Treatment of Clostridioides difficile Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
, it has a narrower spectrum of activity, which limits its effect on the gut microbiome,7 and it is associated ...
Clostridioides (formerly Clostridium) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):137-41 |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
the onset of sexual activity, persons ≤26 years old who have already been exposed to HPV or diagnosed ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
or alcohol, or while still active can increase the risk of these behaviors.12 Use of benzodiazepine ...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6   doi:10.58347/tml.2023.1667a |  Show IntroductionHide Introduction

Influenza Vaccines for 2025-2026

   
The Medical Letter on Drugs and Therapeutics • Sep 29, 2025  (Issue 1738)
with active communication between the cerebrospinal fluid (CSF) and oropharynx, nasopharynx, nose, or ear ...
Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
Med Lett Drugs Ther. 2025 Sep 29;67(1738):153-8   doi:10.58347/tml.2025.1738a |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
treatment retention and may reduce criminal activity, incarceration rates, and social functioning ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
. It has no clinically significant anti-inflammatory activity and is generally less effective than an NSAID in relieving ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction